Salama et al. reported a decreased survival of stage II CRC patients with low content of FoxP3+ T-cells within the tumor (HR 0.65; 95 % CI 0.48–0.89; P = 0.007), whereas the opposite was found when assessing adjacent colonic tissue (HR 1.42; 95 % CI 1.05–1.92; P = 0.023) [11]. This evidence concerns the gene FOXP3 and colorectal carcinoma.